Literature DB >> 25197358

Identification of miR-140-3p as a marker associated with poor prognosis in spinal chordoma.

Ming-Xiang Zou1, Wei Huang2, Xiao-Bin Wang1, Guo-Hua Lv1, Jing Li1, You-Wen Deng1.   

Abstract

OBJECTIVE: To investigate the expression profile of miR-140-3p in formalin-fixed paraffin-embedded (FFPE) tissues of spinal chordoma, and its correlation with the prognosis of spinal chordoma patients.
METHODS: Dysregulated miRNAs in FFPE tissues of spinal chordoma were identified by microarray analysis. MiR-140-3p expression in surgically removed spinal chordoma tissues of 42 spinal chordoma patients (27 males and 15 females, aged 29-76 years) and corresponding nucleus pulposus tissues of 14 patients with disc herniation as the healthy control group (8 males and 6 females, aged 24-73 years) was measured by real-time quantitative RT-PCR assay. The association of miR-140-3p expression with clinicopathologic characteristics of spinal chordoma patients was analyzed. Additionally, we investigated the prognostic significance of miR-140-3p with the use of Kaplan-Meier methods and a Cox proportional hazard model.
RESULTS: The expression of miR-140-3p was significantly higher in chordoma tissues than nucleus pulposus tissues (t = 3.530, P = 0.001). The expression of miR-140-3p positively correlated with surrounding muscle invasion. The Kapan-Meier survival analysis showed that the patients with high miR-140-3p expression had a significantly worse recurrence-free survival than those with a low expression (χ (2) = 31.270, P = 0.000, log-rank test). In addition, univariate and multivariate analyses for recurrence-free survival showed that miR-140-3p expression was an independent prognostic factor for patients with spinal chordoma (HR = 1.361, 95% CI: 1.135-1.633, P = 0.001).
CONCLUSION: Over-expression of miR-140-3p is correlated with recurrence and tumor invasion, suggesting that miR-140-3p could be a new predictor for recurrence and prognosis in patients with spinal chordoma.

Entities:  

Keywords:  MicroRNA; case-control study; chordoma; prognosis; recurrence; spine

Mesh:

Substances:

Year:  2014        PMID: 25197358      PMCID: PMC4152048     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

Review 2.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  Expression of microRNAs in basal cell carcinoma.

Authors:  M Sand; M Skrygan; D Sand; D Georgas; S A Hahn; T Gambichler; P Altmeyer; F G Bechara
Journal:  Br J Dermatol       Date:  2012-08-20       Impact factor: 9.302

4.  Unlocking pathology archives for microRNA-profiling.

Authors:  Kai P Hoefig; Christoph Thorns; Anja Roehle; Christian Kaehler; Kai O Wesche; Dirk Repsilber; Biggi Branke; Marlen Thiere; Alfred C Feller; Hartmut Merz
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

5.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

Review 6.  microRNAs and cancer: an overview.

Authors:  Pedro P Medina; Frank J Slack
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

7.  Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients.

Authors:  Zhao-Qun Deng; Jia-Yu Yin; Qin Tang; Feng-Qiong Liu; Jun Qian; Jiang Lin; Rui Shao; Ming Zhang; Li He
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

Review 8.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11

9.  Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas.

Authors:  Cheng Long; Liang Jiang; Feng Wei; Chuan Ma; Hua Zhou; Shaomin Yang; Xiaoguang Liu; Zhongjun Liu
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

10.  Identifying microRNA/mRNA dysregulations in ovarian cancer.

Authors:  Gregory D Miles; Michael Seiler; Lorna Rodriguez; Gunaretnam Rajagopal; Gyan Bhanot
Journal:  BMC Res Notes       Date:  2012-03-27
View more
  19 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Xiao-Bin Wang; Jing Li
Journal:  Eur Spine J       Date:  2016-10-18       Impact factor: 3.134

3.  miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.

Authors:  Chuan Hu; Yong Zou; Luan-Lian Jing
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

4.  Systematic analysis identifies three-lncRNA signature as a potentially prognostic biomarker for lung squamous cell carcinoma using bioinformatics strategy.

Authors:  Jing Hu; Lutong Xu; Tao Shou; Qiang Chen
Journal:  Transl Lung Cancer Res       Date:  2019-10

5.  Expression and Regulatory Network Analysis of miR-140-3p, a New Potential Serum Biomarker for Autism Spectrum Disorder.

Authors:  Matilde Cirnigliaro; Cristina Barbagallo; Mariangela Gulisano; Carla N Domini; Rita Barone; Davide Barbagallo; Marco Ragusa; Cinzia Di Pietro; Renata Rizzo; Michele Purrello
Journal:  Front Mol Neurosci       Date:  2017-08-10       Impact factor: 5.639

6.  Comparison of the miRNA expression profiles in fresh frozen and formalin-fixed paraffin-embedded tonsillar tumors.

Authors:  Zuzana Vojtechova; Jiri Zavadil; Jan Klozar; Marek Grega; Ruth Tachezy
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

Review 7.  Chordoma: The Quest for Better Treatment Options.

Authors:  Christopher R Heery
Journal:  Oncol Ther       Date:  2016-03-03

8.  Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.

Authors:  Gang Deng; Ronghao Wang; Yin Sun; Chi-Ping Huang; Shuyuan Yeh; Bosen You; Changyong Feng; Gonghui Li; Shenglin Ma; Chawnshang Chang
Journal:  Cell Death Differ       Date:  2021-06-14       Impact factor: 15.828

9.  The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration.

Authors:  Omar Salem; Nese Erdem; Janine Jung; Ewald Münstermann; Angelika Wörner; Heike Wilhelm; Stefan Wiemann; Cindy Körner
Journal:  BMC Genomics       Date:  2016-08-08       Impact factor: 3.969

10.  Myomaker, Regulated by MYOD, MYOG and miR-140-3p, Promotes Chicken Myoblast Fusion.

Authors:  Wen Luo; Erxin Li; Qinghua Nie; Xiquan Zhang
Journal:  Int J Mol Sci       Date:  2015-11-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.